Type II ovarian cancer, which includes high‐grade serous carcinoma, undifferentiated carcinoma and sarcoma, often has mutations in BRCA1 or BRCA2, and TP53, which is consistent with our results (Table 1). This evidence concerns the gene BRCA2 and serous adenocarcinoma.